ImmunoGen, Inc. (NASDAQ:IMGN)

CAPS Rating: 4 out of 5

The Company develops antibody-based anticancer therapeutics.


Player Avatar TMFBreakerThiel (30.23) Submitted: 9/28/2010 12:49:27 PM : Outperform Start Price: $5.75 IMGN Score: +119.42

Hammered because it failed to get an accelerated review from FDA on T-DM1. Does complicate things, but doesn't bear on the efficacy of the drug, which looks strong in HER-2 pos breast cancer that has failed other treatments.

Featured Broker Partners